When was Artera founded?

Artera was founded in 2021 and raised its 1st funding round 2 years after it was founded.

Where is Artera located?

Artera is headquartered in Menlo Park, United States.

Who is the current CEO of Artera?

Andre Esteva of Artera. They have also founded 1 company.

How many employees does Artera have?

As of Sep 30, 2026, the latest employee count at Artera is 152.

Is Artera a funded company?

Artera is a funded company, having raised a total of $135M across 2 funding rounds to date. The company's 1st funding round was a $***** Series A round, raised on Mar 21, 2023.

When was the latest funding round of Artera?

Artera's latest funding was a $***** Series A round on Feb 01, 2024, with participation from 7 investors. Its primary sector is Oncology. In United States, the Oncology sector has seen $6.58B in funding in 2026 to date.

Where does Artera rank among its competitors?

Artera ranks 2nd amongst 79 active competitors, of which 23 are funded. It stands 2nd in terms of total funding among its competitors. The most recent competitor to raise funding was Tempus, which secured $460M in Jul, 2026.

Who are the top competitors of Artera?

Artera's top competitors include Tempus, Personalis and 4baseCare. Among them, Tempus secured the most recent funding round in July, 2026.

Artera - 2026 Company Profile, Team, Funding & Competitors

Company Details

AI-derived prognostic biomarker test for cancer detection. The company offers an AI-enabled test called the ArteraAI prostate test, which provides predictive and prognostic results for patients with localized prostate cancer. The test analyzes multiple characteristics of the individual patient, empowering doctors with personalized data for treatment planning.

Website: artera.ai
Social
Email ID: *****@artera.ai

Key Metrics

Founded Year

2021

Location

Menlo Park, United States

Stage

Series A

Total Funding

$135M in 2 rounds

Latest Funding Round

Series A, Feb 01, 2024, $*****

Investors

Walden Catalyst & 24 more

Ranked

2^nd among 79 active competitors

Employee Count

152 as on Sep 30, 2026

Similar Companies

OpenEvidence & 2969 more

View Artera's full profile

Artera is associated with 2 legal entities given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Reports
ARTERA INC. CIN: 32079761444 , United States, Deadpooled	Jun 18, 2021	-	-	-
ARTERA, INC. CIN: 871224645 , United States, Active	Dec 31, 1999	-	90 (As on Dec 31, 2024)	-

Artera has raised a total funding of $135M over 2 rounds. Its first funding round was on Mar 21, 2023. Its latest funding round was a Series A round on Feb 01, 2024 for $*****. 7 investors participated in its latest round. Artera has 13 institutional investors and 12 angel investors.

Here is the list of recent funding rounds of Artera:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Feb 01, 2024	4028946	Series A	9687938	3217928	2434428	6236283
Mar 21, 2023	7257908	Series A	9679164	9215460	Coatue & 16 more	A&E Investments

Access funding benchmarks and valuations. Sign up today!

View details of Artera's funding rounds and investors

The founders of Artera are Andre Esteva and Felix Feng. Andre Esteva is the CEO of Artera.

Here are the details of Artera's key team members:

Andre Esteva: Co-Founder & CEO of Artera and founder of 1 other company.
Contact Info: 1 email address
Felix Feng: Co-Founder of Artera.

View details of Artera's Founder profiles and Board Members

Artera's employee count trend

Artera has 152 employees as of Sep 26. Here is Artera's employee count trend over the years:

Uncover Artera's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Artera include Tempus, Personalis and 4baseCare. Here is the list of Top 10 competitors of Artera, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Tempus 2015, Chicago (United States), Public	Developer of genomic testing and artificial intelligence tools for medicine	$1.05B	T. Rowe Price, New Enterprise Associates ... & 11 others	78/100
2nd	Artera 2021, Menlo Park (United States), Series A	AI-derived prognostic biomarker test for cancer detection	$135M	Yali Capital, Walden Catalyst & 23 others	69/100
3rd	Personalis 2011, Menlo Park (United States), Acquired	Provider of genomic sequencing and diagnosis software for the healthcare industry	$87.3M	Abingworth, Lightspeed Venture Partners & 5 others	68/100
4th	4baseCare 2018, Bengaluru (India), Series B	Provider of precision oncology solutions, including genomic testing and digital health	$25.9M	Tremis Consultancy, Yali Capital & 41 others	67/100
5th	MDxHealth 2003, Irvine (United States), Public	Provider of epigenetic tests for personalized cancer assessment and treatment	-	Kreos Capital, Eiffel Investment Group & 13 others	62/100
6th	CancerIQ 2013, Chicago (United States), Series B	Cloud-based platform to doctors, for identifying cancer risk patients and delivering care plans	$24.8M	Amgen, Decathlon Capital Partners & 11 others	59/100
7th	Imagene 2020, Tel Aviv (Israel), Series B	Provider of an AI-based cancer diagnosis and precision medicine planning software for healthcare providers	$45M	Blumberg Capital, Katao & 5 others	58/100
8th	Opko Health 1991, Miami (United States), Public	Provider of molecular diagnostic products	-	Gates, Oracle & 1 others	55/100
9th	Genomate Health 2022, Cambridge (United States), Series A	AI-based computational system cancer treatment decisions	$10.4M	Plug and Play Tech Center, STRT	52/100
10th	ProteoMediX 2010, Schlieren (Switzerland), Acquired	Developer of next-generation blood test for prostate cancer	$17.6M	Altos Ventures Management, Venture Kick & 3 others	51/100